GlassScriptPhysician profile
Leonid Kleynberg
NPI 1891750212
$12,397.98
in general payments reported to CMS, 2019-2025
73 companies · $1,554 in 2025
The $1,554 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,683 · 2020: $1,794 · 2021: $2,860 · 2022: $2,127 · 2023: $1,343 · 2024: $1,036 · 2025: $1,554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,885 · Education: $48.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,884.62 |
| Education | $48.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,616.76 | 2019-2025 | Opdivo, Opdualag |
| Incyte Corporation | $1,331.27 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Janssen Biotech, INC. | $1,231.40 | 2019-2025 | Rybrevant, Talvey, Tecvayli |
| Amgen INC. | $764.75 | 2019-2022 | |
| Pfizer INC. | $736.37 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $570.70 | 2019-2025 | Calquence, Enhertu |
| Merck Sharp & Dohme LLC | $498.37 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $387.19 | 2019-2025 | |
| Eisai INC. | $326.41 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $299.91 | 2019-2024 | |
| Genzyme Corporation | $241.08 | 2020-2025 | |
| Spectrum Pharmaceuticals INC. | $234.57 | 2023-2025 | Rolvedon |
| Cti Biopharma Corp. | $207.71 | 2022-2023 | Vonjo |
| Puma Biotechnology, INC. | $206.23 | 2019-2025 | |
| Celgene Corporation | $193.85 | 2021-2025 | Reblozyl |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonid Kleynberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.